Management of brain metastases in tyrosine kinase inhibitor-Naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1070-1077

  Magnuson, William J ^a   Lester Coll, Nataniel H ^a   Wu, Abraham J ^b   Yang, T Jonathan ^b   Lockney, Natalie A ^b   Gerber, Naamit K ^b   Beal, Kathryn ^b   Amini, Arya ^c   Patil, Tejas ^c   Kavanagh, Brian D ^c   Camidge, D Ross ^c   Braunstein, Steven E ^d   Boreta, Lauren C ^d   Balasubramanian, Suresh K ^e   Ahluwalia, Manmeet S ^e   Rana, Niteshkumar G ^f   Attia, Albert ^f   Gettinger, Scott N ^a   Contessa, Joseph N ^a   Yu, James B ^a   Chiang, Veronica L ^a   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTANT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR INVASION; WHOLE BRAIN RADIOTHERAPY; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOSURGERY; SALVAGE THERAPY; SECONDARY; SKULL IRRADIATION; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 85016642260     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.7144     Document Type: Article

References (30)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004
3. Shin DY, Na II, Kim CH, et al: EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9:195-199, 2014
4. Li C, Fang R, Sun Y, et al: Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6:e28204, 2011
5. Eichler AF, Chung E, Kodack DP, et al: The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8:344-356, 2011
6. Fink KR, Fink JR: Imaging of brain metastases. Surg Neurol Int 4:S209-S219, 2013 (suppl 4)
7. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
8. Gerber NK, Yamada Y, Rimner A, et al: Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 89:322-329, 2014
9. Magnuson WJ YJ, Guillod PD, Gettinger SN, et al: Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys 95:673-679, 2016
10. Khozin S, Blumenthal GM, Jiang X, et al: U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19:774-779, 2014
11. Iuchi T, Shingyoji M, Sakaida T, et al: Phase II trial of gefitinib alone without radiation therapy for Japanese patientswith brain metastases from EGFRmutant lung adenocarcinoma. Lung Cancer 82: 282-287, 2013
12. Park SJ, Kim HT, Lee DH, et al: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77:556-560, 2012
13. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
14. Han JY, Park K, Kim SW, et al: First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122-1128, 2012
15. Fine JP: A proportional hazards model for the subdistribution of a competing risk. Stat Med 94: 496-509, 1999
16. Wu YL, Zhou C, Cheng Y, et al: Erlotinib as second-line treatment in patients with advanced nonsmall-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann Oncol 24:993-999, 2013
17. Soon YY, Leong CN, Koh WY, et al: EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis. Radiother Oncol 114:167-172, 2015
18. Ashworth A, Rodrigues G, Boldt G, et al: Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 82:197-203, 2013
19. Ashworth AB, Senan S, Palma DA, et al: An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 15: 346-355, 2014
20. Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 13:8-10, 1995
21. Rami-Porta R, Crowley JJ, Goldstraw P: The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15:4-9, 2009
22. Yu HA, Sima CS, Huang J, et al: Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:346-351, 2013
23. Johung KL, Yao X, Li F, et al: A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res 19:5523-5532, 2013
24. Spano JP, Fagard R, Soria JC, et al: Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives. Ann Oncol 16:189-194, 2005
25. Wang TJ, Saad S, Qureshi YH, et al: Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Neuro Oncol 17: 1022-1028, 2015
26. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
27. Soffietti R, Kocher M, Abacioglu UM, et al: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 31:65-72, 2013
28. Habets EJ, Dirven L, Wiggenraad RG, et al: Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study. Neuro Oncol 18:435-444, 2016
29. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 15: 387-395, 2014
30. National Comprehensive Cancer Network: Central Nervous System Cancers (Version 1.2015). https://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site